Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer

<table>Kaplan-Meier analysis of overall survival <math id="M46" xmlns="http://www.w3.org/1998/Math/MathML"><mo stretchy="false">(</mo><mi>N</mi><mo>=</mo><mn>44</mn><mo stretchy="false">)</mo><mo>.</mo></math></table>

Journal of Oncology

fig2

Figure 2

Figure 2: Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer 